Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet dysfunction in renal failure.

Paola Boccardo1, Giuseppe Remuzzi, Miriam Galbusera

  • 1Mario Negri Institute for Pharmacological Research, Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy.

Seminars in Thrombosis and Hemostasis
|October 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.

Journal of the American Society of Nephrology : JASN·2015
Same author

International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology.

Lancet (London, England)·2015
Same author

Rare diseases and effective treatments: are we delivering?

Lancet (London, England)·2015
Same author

Direct reprogramming of human bone marrow stromal cells into functional renal cells using cell-free extracts.

Stem cell reports·2015
Same author

Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury.

Scientific reports·2015
Same author

Need for chronic kidney disease prevention programs in disadvantaged populations.

Clinical nephrology·2015
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same journal

Pediatric Pulmonary Infarction and Infarction-Like Pulmonary Injury: An Etiology-Oriented Narrative Review.

Seminars in thrombosis and hemostasis·2026
Same journal

Comparison of the Coagulation Profile Following Treatment of Major Surgical Haemorrhage with Fresh Frozen Plasma or Fibrinogen Concentrate.

Seminars in thrombosis and hemostasis·2026
See all related articles

End-stage renal disease patients experience bleeding and clotting issues due to platelet dysfunction caused by uremic toxins. Dialysis helps but doesn't fully resolve these complex hemostatic disorders.

Area of Science:

  • Nephrology
  • Hematology
  • Cardiovascular Medicine

Background:

  • Patients with end-stage renal disease (ESRD) exhibit complex hemostatic disorders, primarily affecting primary hemostasis.
  • Uremic patients present with bleeding diathesis, characterized by platelet dysfunction and impaired platelet-vessel wall interaction.
  • Despite reduced platelet function, ESRD patients face a high incidence of thrombotic and cardiovascular complications.

Purpose of the Study:

  • To investigate the hemostatic abnormalities in end-stage renal disease patients.
  • To understand the role of uremic toxins in platelet dysfunction.
  • To examine the impact of dialysis on platelet function and thrombotic risk in uremic patients.

Main Methods:

  • Review of literature on hemostasis in end-stage renal disease.

Related Experiment Videos

  • Analysis of platelet function tests in uremic patients.
  • Examination of pathological features in renal diseases involving platelets.

    • Main Results:

    • Platelet dysfunction in uremia is partly attributed to circulating uremic toxins.
    • Dialysis partially corrects platelet abnormalities but does not eliminate hemorrhage risk.
    • Hemodialysis may increase bleeding risk due to platelet activation by artificial surfaces.
    • Thrombocytopenia and thrombosis are common in renal diseases, with platelets playing a direct role in glomerular disease pathogenesis.

    Conclusions:

    • End-stage renal disease is associated with significant hemostatic challenges, including bleeding and thrombotic risks.
    • Uremic toxins critically impair platelet function, contributing to bleeding diathesis.
    • Platelets are implicated in the pathogenesis of glomerular diseases, necessitating further research into therapeutic strategies.